Compare JOE & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | XENE |
|---|---|---|
| Founded | 1936 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | N/A | 2014 |
| Metric | JOE | XENE |
|---|---|---|
| Price | $60.27 | $44.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $53.55 |
| AVG Volume (30 Days) | 210.0K | ★ 834.7K |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ 53.79 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $488,689,000.00 | $7,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $207.88 |
| P/E Ratio | $33.76 | ★ N/A |
| Revenue Growth | ★ 26.89 | N/A |
| 52 Week Low | $40.19 | $26.74 |
| 52 Week High | $61.82 | $45.01 |
| Indicator | JOE | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 65.58 | 70.90 |
| Support Level | $55.61 | $39.09 |
| Resistance Level | $61.82 | $45.01 |
| Average True Range (ATR) | 1.50 | 1.44 |
| MACD | 0.02 | 0.50 |
| Stochastic Oscillator | 74.80 | 94.99 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.